JP2012506904A5 - - Google Patents

Download PDF

Info

Publication number
JP2012506904A5
JP2012506904A5 JP2011534455A JP2011534455A JP2012506904A5 JP 2012506904 A5 JP2012506904 A5 JP 2012506904A5 JP 2011534455 A JP2011534455 A JP 2011534455A JP 2011534455 A JP2011534455 A JP 2011534455A JP 2012506904 A5 JP2012506904 A5 JP 2012506904A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
active ingredient
pharmaceutically active
mesoporous
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011534455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506904A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SG2009/000053 external-priority patent/WO2010050897A1/en
Publication of JP2012506904A publication Critical patent/JP2012506904A/ja
Publication of JP2012506904A5 publication Critical patent/JP2012506904A5/ja
Pending legal-status Critical Current

Links

JP2011534455A 2008-10-28 2009-02-18 難水溶性成分のためのメソ多孔性材料賦形剤 Pending JP2012506904A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10901608P 2008-10-28 2008-10-28
US61/109,016 2008-10-28
PCT/SG2009/000053 WO2010050897A1 (en) 2008-10-28 2009-02-18 Mesoporous material excipients for poorly aqueous soluble ingredients

Publications (2)

Publication Number Publication Date
JP2012506904A JP2012506904A (ja) 2012-03-22
JP2012506904A5 true JP2012506904A5 (cg-RX-API-DMAC7.html) 2012-05-10

Family

ID=42129067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011534455A Pending JP2012506904A (ja) 2008-10-28 2009-02-18 難水溶性成分のためのメソ多孔性材料賦形剤

Country Status (5)

Country Link
US (1) US8778401B2 (cg-RX-API-DMAC7.html)
EP (1) EP2349336B1 (cg-RX-API-DMAC7.html)
JP (1) JP2012506904A (cg-RX-API-DMAC7.html)
KR (1) KR20110110097A (cg-RX-API-DMAC7.html)
WO (1) WO2010050897A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
WO2012035074A1 (en) 2010-09-14 2012-03-22 Nanologica Ab Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients
BR112013031702B1 (pt) 2011-06-20 2021-11-03 H. Lundbeck A/S Composto 1-piperazino-3-fenil-indano deuterado, composição farmacêutica que o compreende e uso do referido composto ou da referida composição
GB201212866D0 (en) * 2012-07-20 2012-09-05 Formac Pharmaceuticals Nv Dry granulates of mesoporous silica powders
CN105188720A (zh) 2012-11-06 2015-12-23 西格丽德治疗公司 用作药物或膳食活性成分的多孔硅材料
WO2014100522A1 (en) 2012-12-21 2014-06-26 National Health Research Institutes Mesoporous silica nanoparticles for oil absorption
KR20160137626A (ko) * 2014-03-31 2016-11-30 메사추세츠 인스티튜트 오브 테크놀로지 제약상 활성 종을 포함하는 화합물을 함유한 다공성 물질
CN104027814B (zh) * 2014-05-29 2016-02-24 福州大学 一种通过氨基修饰后双重载药的介孔二氧化硅
US20170135991A1 (en) * 2014-08-01 2017-05-18 Glenmark Pharmaceuticals S.A. NANOPARTICULATE FORMULATION COMPRISING A mPGES-1 INHIBITOR
EP3174527B1 (en) * 2014-08-01 2021-02-17 Johnson & Johnson Consumer Inc. Dosage form of sodium ibuprofen dihydrate on mesoporous silica
GB201502073D0 (en) 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
US10252251B2 (en) 2015-08-28 2019-04-09 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Production of organic materials using solid catalysts
SG11201810628XA (en) * 2016-06-03 2018-12-28 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
CN106755231B (zh) * 2016-11-29 2020-11-24 大连工业大学 一种血管紧张素转化酶抑制肽的提取方法
KR20190109452A (ko) 2017-01-20 2019-09-25 엠 이티 피 파마 아게 대기 오염 물질에의 노출 위험을 감소시키기 위한 비강 약학적 조성물
US11246931B2 (en) 2017-05-19 2022-02-15 Tokuyama Corporation Active pharmaceutical ingredient carrier and production method of the same
CA3263127A1 (en) 2018-11-07 2025-03-21 Disruptive Pharma Ab NEW AMORPHIC ACTIVE PHARMACEUTICAL INGREDIENTS
US11123309B2 (en) 2018-11-15 2021-09-21 Imam Abdulrahman Bin Faisal University Methods for drug delivery, tumor imaging, and oxidative dehydrogenation using hierarchical ZSM-5 complex
WO2020114853A1 (en) 2018-12-03 2020-06-11 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine
US11458092B2 (en) 2018-12-14 2022-10-04 NuVessl, Inc. Composition with enhanced passenger molecule loading
US20220096398A1 (en) * 2019-01-31 2022-03-31 Macquarie University Complexes and compositions comprising probucol and uses thereof
JP7260353B2 (ja) * 2019-03-25 2023-04-18 株式会社ファンケル コエンザイムｑ１０の固体分散体
GB201909137D0 (en) * 2019-06-25 2019-08-07 Univ Aston Mesoporous polymeric particulate material
JP2021042173A (ja) * 2019-09-12 2021-03-18 株式会社ファンケル クルクミン固体分散体
JP2023524661A (ja) * 2020-05-06 2023-06-13 ディスラプティヴ ファーマ エービー 新規非晶質活性医薬成分
WO2022235934A2 (en) * 2021-05-06 2022-11-10 The Chinese University Of Hong Kong Realizing the nano-amorphous state of materials inside nano-porous templates
CN115300448A (zh) * 2021-05-06 2022-11-08 香港中文大学 在纳米多孔模板内实现材料的纳米非晶态
US12458602B2 (en) 2021-05-06 2025-11-04 The Chinese University Of Hong Kong Realizing the nano-amorphous state of materials inside nano-porous templates

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US5922299A (en) 1996-11-26 1999-07-13 Battelle Memorial Institute Mesoporous-silica films, fibers, and powders by evaporation
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US7172770B2 (en) * 2001-02-19 2007-02-06 Board Of Regents, The University Of Texas System Mesoporous compositions for use in drug delivery
US6630170B2 (en) * 2001-04-26 2003-10-07 Board Of Regents The University Of Texas System Mesoporous compositions and method of preparation
CA2448825C (en) * 2001-06-22 2009-08-11 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drug
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
WO2005082277A1 (en) * 2004-02-18 2005-09-09 Stanford University Drug delivery systems using mesoporous oxide films
WO2005110592A1 (en) * 2004-05-17 2005-11-24 Yki, Ytkemiska Institutet Ab Mesoporous particles loaded with active substance

Similar Documents

Publication Publication Date Title
JP2012506904A5 (cg-RX-API-DMAC7.html)
Patel et al. Xanthan gum derivatives: Review of synthesis, properties and diverse applications
US20240293327A1 (en) Monolithic tablets based on carboxyl polymeric complexes for controlled drug release
Javanbakht et al. Carboxymethyl cellulose-based oral delivery systems
CN112004520B (zh) 包括具有触发脉冲药物释放的胃内滞留筏形成系统的调节释放药物粉末组合物
JP2008503475A5 (cg-RX-API-DMAC7.html)
Shilpa et al. Controlled delivery of drugs from alginate matrix
JP2009542795A5 (cg-RX-API-DMAC7.html)
CA3097737A1 (en) Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
CN105283203A (zh) 用于热熔挤出的组合物以及通过使用该组合物制备热熔挤出物的方法
Bera et al. Facile synthesis and characterization of tailor-made pectin-gellan gum-bionanofiller composites as intragastric drug delivery shuttles
Nayak et al. Gellan gum-based nanomaterials in drug delivery applications
WO2011135591A2 (en) Novel tablet composition of polyallylamine polymers
JP2011241218A5 (cg-RX-API-DMAC7.html)
Mali et al. Delivery of drugs using tamarind gum and modified tamarind gum: A review
Olayemi et al. Formulation and evaluation of Cyperus esculentus (Tiger Nut) starch-alginate microbeads in the oral delivery of ibuprofen
WO2008086844A2 (en) Co-precipitate, method for preparing the same and uses thereof
JP2011513393A5 (cg-RX-API-DMAC7.html)
JP2008528456A (ja) 親油性結晶性物質としてカンデサルタンシレキセチルを含む新規な医薬組成物
RU2004117848A (ru) Система продолжительного высвобождения растворимого лекарственного средства
JP2010521437A5 (cg-RX-API-DMAC7.html)
JP2002536318A5 (cg-RX-API-DMAC7.html)
Hasnain et al. Graft copolymers of chitosan in drug delivery applications
Nokhodchi et al. Application of polymer combinations in extended release hydrophilic matrices
Das et al. Gellan gum–based microparticles and beads for sustained drug delivery